Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial

By sjmartinez • April 4, 2025

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Patel PA, Collins RH Jr, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial. Blood Cancer J. 2025 Apr 3;15(1):55. doi: 10.1038/s41408-025-01258-0. PMID: 40180903.

Tags: Hematology/Oncology, Publications

Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial

Ueno M, Yoo C, Ren Z, Furuse J, Kelley RK, Chan SL, Edeline J, Klümpen HJ, Yau T, Verslype C, Ozaka M, Bouattour M, Park[...]

Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC

Brown T, Lara MS, Jiang F, Garon EB, Goldman JW, Riess JW, Blakely CM. Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC. JTO[...]

Susan Ettner, PhD and Dennis J. Slamon, MD, PhD Elected to the National Academy of Medicine

The UCLA Department of Medicine (DoM) is pleased to congratulate Susan Ettner, PhD and Dennis Slamon, MD, PhD, on their election to the National Academy[...]